Oncodesign Precision Medicine Société anonyme (EPA:ALOPM)

EPA:ALOPM Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Operating Revenue	0.26	0.22	1.4	8.02
Other Revenue	1.55	1.42	0.34	0.27
Revenue	1.81	1.64	1.74	8.29
Revenue Growth (YoY)	10.70%	-6.02%	-79.03%	-
Cost of Revenue	-9.47	6.51	8	7.56
Gross Profit	11.28	-4.88	-6.26	0.73
Selling, General & Admin	2.59	2.59	3.31	2.08
Other Operating Expenses	0.11	0.08	0.12	0.1
Operating Expenses	5.58	2.93	3.69	2.34
Operating Income	5.7	-7.81	-9.94	-1.61
Interest Expense	-0.19	-0.44	-0.15	-0.12
Interest & Investment Income	-	0.3	0.24	0
Currency Exchange Gain (Loss)	-	-0	-0.02	0
Other Non Operating Income (Expenses)	-0.03	-	-	0
EBT Excluding Unusual Items	5.48	-7.95	-9.86	-1.72
Gain (Loss) on Sale of Investments	-	-0.02	0.01	-
Other Unusual Items	-	-0.35	0	-0
Pretax Income	5.48	-8.31	-9.85	-1.72
Income Tax Expense	-	-1.1	-1.76	-1.49
Net Income	5.48	-7.21	-8.09	-0.23
Net Income to Common	5.48	-7.21	-8.09	-0.23
Shares Outstanding (Basic)	-	18	17	17
Shares Outstanding (Diluted)	-	18	17	17
Shares Change (YoY)	-	9.16%	-0.48%	-
EPS (Basic)	-	-0.40	-0.49	-0.01
EPS (Diluted)	-	-0.40	-0.49	-0.01
Gross Margin	623.20%	-298.27%	-	8.84%
Operating Margin	314.92%	-477.48%	-571.55%	-19.41%
Profit Margin	302.76%	-440.94%	-465.04%	-2.79%
EBITDA	8.58	-7.55	-9.69	-1.45
EBITDA Margin	474.03%	-	-	-17.43%
D&A For EBITDA	2.88	0.26	0.25	0.16
EBIT	5.7	-7.81	-9.94	-1.61
EBIT Margin	314.92%	-	-	-19.41%
Revenue as Reported	1.81	1.64	1.75	8.32

Source: S&P Global Market Intelligence. Standard template. Financial Sources.